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1 Ask: Research Question
Would adding EntrestoTM
(Sacubitril/valsartan) as 
adjunctive therapy improve 
morbidity/ mortality rates vs 
traditional ACEi and beta-
blocker therapy for heart failure 
patients with reduced ejection 
fraction (EF <40%)?
2a Acquire: Search Terms
Search terms: heart failure, 




Patient/Client group. Heart 
failure patients with reduced 
ejection fraction                                  
Intervention: Switching ACEi for 
sacubitaril/ valsartan 
Comparison: Patients receiving 
sacubitaril/ valsartan vs ACEi 
therapy
Outcome: Sacubitaril/ valsartan 
patients had a reduction in 
cardiovascular death incidence
2b Acquire: Selected Articles 
McMurray et al. (2014): A 
double blind study comparing 
patient morbidly and mortality 
rates of Sacubitril/valsartan vs 
ACEi
Yanci et al. (2017): Systematic 
review of Heart Failure signs 
and symptoms, diagnosing, and 
current treatment options
Nagarajan et al. (2011): Systematic review of 
BNP’s effects within the body and its response 
to worsening heart failure
3a Appraise: Study Quality 
McMurray et al (2014): Level II evidence; 
evidence obtained from one well-designed 
randomized trail comparing 
Sacubitril/valsartan to Enalapril in Heart failure 
patients (n= 8,436) 
Yancy et al. (2017): Level I evidence; 
Systematic review of all literature that can be 
generalized to persons with heart failure with 
reduced ejection fraction. Official American 
Heart Association Guidelines.
Nagarajan et al. (2011): Level V evidence; 
evidence obtained through review of many 
descriptive and qualitative studies (n= 57 
studies) about BNP function and its respond in 
heart failure
3b Appraise: Study Results 
McMurray et al. (2014): Heart failure patients 
with reduced ejection fraction receiving 
equitant doses of sacubitril/valsartan vs 
enalapril had a reduced rate of mortality 
related to cardiovascular deaths and a 
reduced rate of hospitalizations, 21.8% vs 
26.5% respectively (hazard ratio, 0.80; 95% 
CI, 0.73 to 0.87; P <0.001) 
Yancy et al. (2017): Appraised all major 
studies related to heart failure, 
recommendations to start ACEi first line, 
adding in B-blocker when tolerated with 
Spironolactone added when ACEi and B-
blocker are not effective. Loop diuretics 
suggested for volume overload relief 
Nagarajan et al. (2011): Appraised 57 
articles showing the BNP has the effects 
of vasoactive peptides within the body that 
act by blocking vasoconstriction, sodium 
reuptake and cardiac remodeling. BNP is 
also broken down by neprilysin which is 
inhibited by sacubitril.
4 Apply: Conclusions for Practice
McMurray et al. (2014): This study shows 
that when a patient is already on 
maximum pharmacological therapy 
(ACEi/ARB, B-Blocker and 
spironolactone) switching the ACEi/ARB 
to sacubitril/ valsartan will improve their 
mortality rates and reduce their number of 
hospitalizations.
A review of other literature showed there 
are many positive effects of BNP 
(vasoconstriction, sodium reuptake and 
cardiac remodeling) in patients with heart 
failure and blocking the break down of 
BNP will help keep it around longer and 
increase its effectiveness
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Mary is a 64 year old female with Heart Failure with 
reduced ejection fraction. She has been hospitalized 
twice in the last year for exacerbations related to heart 
failure. She is still experiencing symptoms of heart failure 
after being on maximum ACEi, B-Blocker and 
Spironolactone therapy.
Clinical Bottom Line
Yes, sacubitril/valsartan improved the mortality rates of heart failure patients on maximum 
therapy (ACEi, B-Blocker and Spironolactone) when compared to an ACEi and B-Blocker
